阿托伐他汀对高血压患者血管内皮细胞损伤修复及PERK、IRE1α、BiP、Ero1-Lα蛋白表达的影响

发布时间：2018-03-10 19:50

  本文选题：阿托伐他汀　切入点：高血压　出处：《中国老年学杂志》2017年19期 　论文类型：期刊论文

【摘要】：目的探讨阿托伐他汀对高血压患者血管内皮细胞损伤修复及PERK、IRE1α、Bi P、Ero1-Lα蛋白表达的影响。方法 88例高血压患者通过随机数表法分为研究线和对照组各44例。对照组采用高血压基础干预措施,研究组在对照组干预基础上加用阿托伐他汀,两组均持续治疗2个月。对比两组临床疗效,分析治疗前后两组内质网应激(ER stress)标记蛋白(Ero1-Lα、Bi P、IRE1α、PERK)、血管内皮功能指标[内皮素(ET)、一氧化氮(NO)、肱动脉血流介导血管扩张率(FMD)]、血清炎症因子[白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α、高敏C反应蛋白(hs-CRP)]水平变化。结果研究组总有效率高于对照组(P0.05);治疗前两组Ero1-Lα、Bi P、IRE1α、PERK光密度值对比无明显差异(P0.05),治疗后两组各指标水平较治疗前降低,且研究组均低于对照组(均P0.05);治疗前两组ET、NO、FMD水平比较无明显差异(P0.05),治疗后两组各指标水平较治疗前改善,且研究组ET水平低于对照组,NO、FMD水平高于对照组(P0.05);治疗前研究组IL-6、TNF-α、hs-CRP水平与对照组比较无明显差异(P0.05),治疗后两组炎症因子水平均降低,且研究组均低于对照组(P0.05)。结论采用阿托伐他汀治疗高血压患者可有效降低PERK、IRE1α、Bi P、Ero1-Lα蛋白及血清炎症因子表达水平,促使血管内皮细胞损伤修复,提高治疗效果。
[Abstract]:Objective to investigate the effects of Atto vastatin on the repair of vascular endothelial cell injury and the expression of PERKN IRE1 伪 Bi PERO1-L 伪 protein in hypertensive patients. Methods 88 patients with hypertension were divided into two groups by random number method: 44 cases in the study line and 44 cases in the control group. Basic interventions with hypertension, The study group was treated with Atto vastatin on the basis of the intervention of the control group, and the two groups were treated continuously for 2 months. Endoplasmic reticulum stress (ER / S) marker protein Ero1-L 伪 (Bi PnIRE1 伪), vascular endothelial function (et), nitric oxide (no), brachial artery blood flow mediated vasodilation (FMDR), serum inflammatory factor (IL-6) and tumor necrosis were analyzed before and after treatment. Results the total effective rate in the study group was higher than that in the control group (P 0.05), and there was no significant difference in the optical density of the two groups before and after treatment (P 0.05). There was no significant difference in FMD level between the two groups before and after treatment (P 0.05), and the levels of each index in the two groups were improved after the treatment compared with the control group (P 0.05), and there was no significant difference in FMD between the two groups before and after treatment. The level of et in the study group was lower than that in the control group, and the level of FMD in the study group was higher than that in the control group (P 0.05), and the level of IL-6 TNF- 伪 hs-CRP in the study group was not significantly different from that in the control group before treatment. Conclusion the treatment with Atto vastatin can effectively reduce the expression of PERKE IRE1 伪 and serum inflammatory factors, promote the repair of vascular endothelial cell injury and improve the therapeutic effect.
【作者单位】： 上海市浦东新区公利医院心血管内科;
【基金】：上海市浦东新区卫生系统学科带头人附带课题(No.PWRd2015-11)
【分类号】：R544.1
，

本文编号：1594819